The e-prescribing market is valued at $4.21 billion in 2025, growing at 24.19% CAGR to reach $12.44 billion by 2030 (Fortune Business Insights). More than 75% of US physicians now send prescriptions electronically. E-prescribing has reduced medication errors by up to 30% in published clinical studies. And Electronic Prescribing of Controlled Substances (EPCS) — the DEA-regulated pathway for prescribing Schedule II–V medications electronically — is now mandatory in 30+ US states, with more legislating requirements each year.
The pharmacy software market and the broader healthcare software market operate under a compliance burden that is not analogous to any other software domain. HIPAA mandates specific technical safeguards for any system that touches Protected Health Information. The FDA’s Software as a Medical Device (SaMD) framework — triggered when software meets the definition of a medical device — requires IEC 62304-compliant development, FDA clearance pathways, and post-market surveillance. HL7 FHIR R4 is the federally mandated interoperability baseline. Each of these is not a policy recommendation — it is an enforceable regulatory requirement with penalties for non-compliance.
Building pharmacy or healthcare software without understanding this compliance landscape does not produce faster or cheaper development. It produces regulatory debt that eventually forces expensive redesigns, failed FDA audits, or HIPAA breach investigations.
HL7 FHIR R4: The Mandated Interoperability Baseline
HL7 FHIR (Fast Healthcare Interoperability Resources) R4 is the interoperability standard mandated by the ONC’s 21st Century Cures Act Final Rule (2020/2021). The rule requires any software that meets the definition of “Health IT” to provide standardized API access to patient data using FHIR R4 — including electronic health records, patient portals, and any third-party application that integrates with them.
What FHIR R4 actually is:
- A RESTful API specification with defined resource types (Patient, Medication, MedicationRequest, Observation, DiagnosticReport, etc.)
- SMART on FHIR — an OAuth 2.0 authorization framework layered over FHIR that defines how third-party applications authenticate and request patient data access
- Capability Statements — machine-readable descriptions of what FHIR operations a server supports, used by clients to discover available functionality
For pharmacy software specifically, the FHIR resource types that matter:
MedicationRequest — the FHIR representation of a prescription. A MedicationRequest contains the prescribing provider, the patient, the medication (coded with RxNorm, the standard drug terminology), the dosage instructions, the quantity, the number of refills, and the dispensing pharmacy. Any pharmacy application that needs to receive or process electronic prescriptions from FHIR-compliant EHRs must implement MedicationRequest ingestion.
MedicationDispense — the record of a medication being dispensed to a patient. Closing the prescription loop — linking a MedicationRequest to a MedicationDispense — is the foundation of medication adherence tracking, refill reminders, and the clinical reconciliation workflows that reduce adverse drug events.
AllergyIntolerance and MedicationStatement — the patient’s known allergies and current medication list, used by drug interaction checking algorithms. A pharmacy system that can pull these resources from the patient’s EHR via FHIR has better input data for interaction checking than one that relies on patient-reported information alone.
FHIR R5 (published 2023) is in early adoption for clinical trial and real-world data use cases. The production implementation target for pharmacy software integrating with payer and EHR systems remains FHIR R4 until broader R5 adoption emerges.
NCPDP SCRIPT and EPCS: The Electronic Prescribing Layer
The NCPDP SCRIPT Standard (National Council for Prescription Drug Programs) is the message format used for electronic prescribing transactions between prescribers, pharmacies, and pharmacy benefit managers. While FHIR is the data model standard, NCPDP SCRIPT is the transaction standard for the specific messages that flow through the Surescripts electronic prescribing network.
SCRIPT v2017071 (the current required version) defines message types for:
- NewRx — a new prescription transmitted electronically from prescriber to pharmacy
- RxRenewalRequest/Response — refill requests from pharmacy to prescriber and the prescriber’s response
- RxChangeRequest/Response — modifications to an existing prescription (quantity, formulation changes)
- CancelRx — prescription cancellation
- RxFill — confirmation that a prescription was dispensed
EPCS (Electronic Prescribing of Controlled Substances) adds DEA-specific requirements to the SCRIPT workflow. EPCS requires two-factor authentication for the prescriber at the time of signing (something you know + something you have — typically a hard token or smartphone-based authenticator). The pharmacy software must validate that the incoming controlled substance prescription was signed with a DEA-compliant two-factor process, which requires integration with identity proofing services (Experian, Equifax health) and audit logging that satisfies DEA 21 CFR Part 1311 requirements.
For teams building prescriber-facing software: EPCS two-factor authentication flows are the most common source of user friction complaints in e-prescribing applications and the most common technical reason that prescribers do not adopt EPCS for controlled substances. The UX of the authentication flow — making it fast enough that it does not interrupt clinical workflow — is as important as its technical correctness.
FDA’s 2026 SaMD Guidance: The Regulatory Shift That Expands the Market
The FDA’s January 6, 2026 guidance on clinical decision support software is the most significant regulatory development in healthcare software in recent years. The guidance narrows the FDA’s regulatory perimeter for non-device CDS (clinical decision support) software in ways that expand the commercially viable market for AI-powered pharmacy and clinical decision tools.
What the 2026 guidance changed: Under previous FDA guidance, CDS software that presented a single recommendation to a clinician could be treated as a higher-risk medical device requiring 510(k) clearance. The January 2026 guidance removes this constraint for software where a clinician can independently review the basis for the recommendation and does not primarily rely on the software’s recommendation for clinical action. This is the “intended user” test: if a qualified clinician can understand the recommendation, disagree with it, and override it using their own clinical judgment — the software may fall outside the device boundary.
The practical implication: AI-powered drug interaction checking, adherence risk scoring, formulary recommendation engines, and dosage optimization tools that present recommendations with transparent clinical rationale to prescribers and pharmacists — and where the clinician makes the final decision — are now more clearly in the non-device CDS category. This is not a compliance-free zone: the FDA still expects rigorous clinical validation documentation and post-market monitoring for non-device CDS. But it avoids the 510(k) clearance timeline (typically 6–18 months) and cost ($50,000–$500,000+) for these applications.
What still requires 510(k) clearance: Software where the clinical decision is automated without meaningful human review opportunity, software used for diagnosis without a clinician in the loop, and software that drives treatment decisions in high-acuity settings without override mechanisms. FDA cleared 97% of AI-enabled medical devices via the 510(k) pathway in 2024 — meaning the pathway is functional, but understanding correctly which pathway applies to your specific application scope avoids significant cost and timeline risk.
IEC 62304: What Software as a Medical Device Development Actually Requires
IEC 62304:2006+A1:2015 is the medical device software lifecycle standard. It applies to any software that meets the SaMD definition — which, in pharmacy, includes drug interaction checking algorithms, clinical decision support for medication dosing, pharmacy management systems used in clinical settings, and any software component in a medical device.
The standard defines three software safety classes based on the severity of harm that software failure could cause:
- Class A: No injury or damage to health is possible. The most minimal requirements — a software development plan and release documentation.
- Class B: Non-serious injury is possible. Adds architectural design documentation, detailed design requirements, unit verification, and problem resolution process.
- Class C: Death or serious injury is possible. Adds 100% statement coverage in software testing, bidirectional traceability from requirements to tests, and formal software architecture documentation. This is the class that applies to software controlling drug infusion pumps, radiation therapy planning, or automated diagnostic decisions in life-critical pathways.
For pharmacy software: a drug interaction checking algorithm that could, if incorrect, allow a pharmacist to dispense a contraindicated medication combination is a Class B or Class C system. An administrative pharmacy management system for prescription inventory tracking is Class A. Correctly classifying software items determines the development process requirements — and misclassification (treating Class C software as Class A) is an FDA audit finding.
The development process requirements that matter in practice:
IEC 62304 requires a Software Development Plan that is maintained throughout the project lifecycle — not a one-time document. The plan must specify the development lifecycle model, the configuration management approach (version control, change control), the problem resolution process (how bugs are reported, investigated, and closed), and the testing approach per safety class.
The traceability matrix — linking requirements to design decisions to test cases — is the document that most teams underinvest in and most FDA auditors focus on. A Class C traceability matrix must demonstrate that every requirement has at least one test case that verifies it, every test case traces back to at least one requirement, and the coverage is bidirectional. Tools like PTC Integrity, IBM DOORS, or Polarion ALM support traceability matrix management at the scale that Class C software requires.
HIPAA: Architecture Decisions That Cannot Be Retrofitted
HIPAA’s Security Rule requires administrative, physical, and technical safeguards for any system that creates, receives, maintains, or transmits Protected Health Information (PHI). The technical safeguard requirements that have direct engineering consequences:
Access controls: Role-based access to PHI with the “minimum necessary” principle — each user role can access only the PHI data elements their function requires. In a pharmacy system, a pharmacy technician needs access to prescription fills but not to prescriber DEA numbers or patient mental health records. Implementing role-based PHI scoping in a system with complex data relationships requires deliberate data access layer design — it cannot be added after the fact without a significant refactoring of the access control model.
Audit controls: HIPAA requires audit logs that record access to PHI — who accessed which records, when, and what actions were taken. Audit logs must be tamper-evident, retained for 6 years (under HIPAA) or longer (under some state laws), and exportable for compliance investigations. Designing audit logging from the beginning — as a first-class concern that captures PHI access events at the data layer, not the application layer — is significantly cheaper than retrofitting it after the system is in production.
Transmission security: All PHI transmitted over networks must be encrypted (TLS 1.2 minimum; TLS 1.3 recommended). This includes API communications with EHRs, Surescripts, payers, and any third-party services. PHI cannot be transmitted via email or unencrypted messaging without explicit patient authorization for each disclosure.
Business Associate Agreements (BAA): Every cloud service that touches PHI — including the database hosting provider, the email service used for patient communications, and the analytics platform used for reporting — must have a signed BAA before PHI is processed by that service. Designing a cloud architecture for healthcare without a BAA checklist for every service in the stack is a HIPAA violation waiting to happen.
How we approach this at Insoftex
Healthcare and pharmacy software is the domain where we see the largest gap between what teams think the compliance overhead requires (a privacy policy and HTTPS) and what it actually requires (IEC 62304 software lifecycle, HIPAA technical safeguards designed into the architecture, FHIR R4 implementation with SMART on FHIR authorization, and for SaMD, FDA regulatory strategy before architecture commitment).
For clients building pharmacy applications, clinical decision support, or healthcare data platforms, we include a regulatory scope assessment before any architecture decisions are made — identifying whether the intended use case triggers SaMD classification, which IEC 62304 safety class applies to each software component, and what HIPAA safeguards need to be built into the data layer from day one. The cost of getting this right at the architecture phase is a fraction of the cost of an FDA audit finding or a HIPAA breach investigation.
The healthcare software opportunity is substantial. The companies that build it correctly — with compliance as an architecture input, not a late-stage checkbox — are the ones that win enterprise health system procurement decisions, pass payer audits, and avoid the regulatory incidents that have ended healthcare software companies that treated compliance as a burden rather than a design constraint.
Building pharmacy software, healthcare data platforms, or clinical decision support tools? Our Product Pilot includes a regulatory scope assessment (HIPAA architecture, SaMD classification, IEC 62304 safety class) and FHIR integration architecture review — before you commit to a development approach that may require significant changes to satisfy FDA and ONC requirements.